Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity
- 25 July 2008
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 28 (8), 704-709
- https://doi.org/10.1002/pd.1997
Abstract
Objectives To estimate the combined screening performance of first and early second trimester prenatal serum markers for Down syndrome, in screening for the development of preeclampsia, and analyze the correlation among marker levels, week of onset, and severity of the disease. Methods A retrospective cohort study was carried out on 32 women with preeclampsia and 3044 controls. Serum samples from these pregnancies were assayed for pregnancy‐associated plasma protein‐A (PAPP‐A), alpha‐fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotrophin (hCG), and inhibin‐A. A likelihood ratio and the odds of being affected given a positive result (OAPR) of various combinations of markers were calculated and receiver operating characteristic (ROC) curves analysis was performed. Results In the pregnancies that subsequently developed preeclampsia, first trimester PAPP‐A concentration was significantly lower and concentrations of early second trimester inhibin‐A and hCG significantly elevated. Levels of early second trimester uE3 and AFP were not significantly altered. We also found that inhibin‐A correlates with both onset of the disease and the severity. Conclusion Down syndrome biochemical markers levels are altered in those patients who subsequently developed preeclampsia and may be a useful screening test for preeclampsia. Inhibin‐A is the most predictive marker and correlates with the severity of subsequent preeclampsia and inversely with the week of occurrence of preeclampsia. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- Screening in early pregnancy for pre‐eclampsia using down syndrome quadruple test markersPrenatal Diagnosis, 2006
- First-Trimester or Second-Trimester Screening, or Both, for Down's SyndromeNew England Journal of Medicine, 2005
- First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER Trial)American Journal of Obstetrics and Gynecology, 2004
- Association between fetal nuchal translucency thickness in first trimester and subsequent gestational hypertension and preeclampsiaPrenatal Diagnosis, 2002
- Mid‐trimester triple test levels in early and late onset severe pre‐eclampsiaPrenatal Diagnosis, 2002
- Ultrasound diagnosis of structural abnormalities in the first trimesterPrenatal Diagnosis, 2002
- Correlation Between Second Trimester Maternal Serum Inhibin-A and Human Chorionic Gonadotrophin for the Prediction of Pre-eclampsiaPlacenta, 2000
- Prediction of pre-eclampsia with maternal mid-trimester total renin, inhibin A, AFP and free β-hCG levelsPrenatal Diagnosis, 1999
- Inhibin A and Activin A in the First Trimester of Human PregnancyJournal of Clinical Endocrinology & Metabolism, 1997
- Screening For Down's Syndrome. The Role Of Intact Hcg and Free Subunit MeasurementScandinavian Journal of Clinical and Laboratory Investigation, 1993